MD Anderson Cancer Center
First-year progress in MD Anderson’s Moon Shots Program – CNL
The University of Texas MD Anderson Cancer Center in September 2012 announced its Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. The program initially targets acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung cancer; melanoma; prostate cancer; and triple-negative breast and high-grade serious ovarian cancers. Elizabeth Grimm, Ph.D., interim director and chief scientific officer for MD Anderson’s Moon Shots Program, discusses progress since the effort launched one year ago.
Loading the Audio Player...

Title: First-year progress in MD Anderson’s Moon Shots Program – CNL
Summary: The University of Texas MD Anderson Cancer Center in September 2012 announced its Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. The program initially targets acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung cancer; melanoma; prostate cancer; and triple-negative breast and high-grade serious ovarian cancers. Elizabeth Grimm, Ph.D., interim director and chief scientific officer for MD Anderson’s Moon Shots Program, discusses progress since the effort launched one year ago.
Keywords: cnl, cancer newsline, Acute Myeloid Leukemia, AML, Myelodysplastic Syndrome , MDS, Chronic Lymphocytic Leukemia, cll, melanoma, lung, skin, prostate, cancer, moon shots, moon shot program, breast, ovarian, triple-negative breast cancer, high-grade serous, Elizabeth grimm, extComm, Communications - External
Transcript: